Japan's Astellas to Buy U.S. Drugmaker OSI for $4 Bil.
By wchung | 04 May, 2025
Astellas Pharma Inc., Japan’s No. 2 drug maker, said Monday it will buy U.S. cancer drug company OSI Pharmaceuticals Inc. for $4 billion in cash in a bid to expand its cancer drug business worldwide.
Astellas said it will pay $57.50 per OSI share, up from $52 the Japanese company had offered earlier. The transaction will be completed within a month.
The acquisition is part of Astellas’ drive to expand its cancer drug business worldwide. OSI’s drugs include Tarceva, for lung cancer, which generated $1.2 billion in global sales last year.
The Japanese maker said it hopes to jointly develop cancer drugs with OSI.
Apart from cancer, OSI focuses on oncology, diabetes and obesity treatments.
TOKYO (AP)
Articles
- $15,000 Toyota EV Developed with 100% China Talent, Supply Chain
- Ivan Zhao's Notion Simplifies Work and Life for 100 Million Users
- Survey Shows Rise of Anti-Asian Feelings — and Cause for Optimism
- Judge Edward Chen Sets Up Supreme Court Review of Trump's Mass Deportations
- Rep. Shri Thanedar Introduces Articles of Impeachment Against Trump
Asian American Success Stories
- The 130 Most Inspiring Asian Americans of All Time
- 12 Most Brilliant Asian Americans
- Greatest Asian American War Heroes
- Asian American Digital Pioneers
- New Asian American Imagemakers
- Asian American Innovators
- The 20 Most Inspiring Asian Sports Stars
- 5 Most Daring Asian Americans
- Surprising Superstars
- TV’s Hottest Asians
- 100 Greatest Asian American Entrepreneurs
- Asian American Wonder Women
- Greatest Asian American Rags-to-Riches Stories
- Notable Asian American Professionals